Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:GTXI's Cash-to-Debt is ranked higher than
97% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. NAS:GTXI: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:GTXI' s Cash-to-Debt Range Over the Past 10 Years
Min: 2688.67  Med: No Debt Max: No Debt
Current: No Debt
Interest Coverage No Debt
NAS:GTXI's Interest Coverage is ranked higher than
96% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:GTXI: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:GTXI' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: -22.80
Beneish M-Score: -4.37
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE % -116.20
NAS:GTXI's ROE % is ranked lower than
83% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. NAS:GTXI: -116.20 )
Ranked among companies with meaningful ROE % only.
NAS:GTXI' s ROE % Range Over the Past 10 Years
Min: -397.59  Med: -118.8 Max: 71.17
Current: -116.2
-397.59
71.17
ROA % -73.26
NAS:GTXI's ROA % is ranked lower than
79% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. NAS:GTXI: -73.26 )
Ranked among companies with meaningful ROA % only.
NAS:GTXI' s ROA % Range Over the Past 10 Years
Min: -118.97  Med: -45.92 Max: 25.08
Current: -73.26
-118.97
25.08
ROC (Joel Greenblatt) % -65487.37
NAS:GTXI's ROC (Joel Greenblatt) % is ranked lower than
96% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. NAS:GTXI: -65487.37 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:GTXI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -128476.47  Med: -4247.18 Max: 522.64
Current: -65487.37
-128476.47
522.64
3-Year EBITDA Growth Rate -36.20
NAS:GTXI's 3-Year EBITDA Growth Rate is ranked lower than
90% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. NAS:GTXI: -36.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:GTXI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -15.9 Max: 10.4
Current: -36.2
0
10.4
3-Year EPS without NRI Growth Rate -43.30
NAS:GTXI's 3-Year EPS without NRI Growth Rate is ranked lower than
85% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. NAS:GTXI: -43.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:GTXI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -54.8  Med: -7.2 Max: 192.4
Current: -43.3
-54.8
192.4
GuruFocus has detected 1 Warning Sign with GTx Inc $NAS:GTXI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:GTXI's 10-Y Financials

Financials (Next Earnings Date: 2017-08-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

GTXI Guru Trades in Q1 2016

Paul Tudor Jones 34,033 sh (unchged)
» More
Q2 2016

GTXI Guru Trades in Q2 2016

Paul Tudor Jones 34,033 sh (unchged)
» More
Q3 2016

GTXI Guru Trades in Q3 2016

Jim Simons 72,906 sh (New)
Paul Tudor Jones 34,033 sh (unchged)
» More
Q4 2016

GTXI Guru Trades in Q4 2016

Jim Simons Sold Out
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with GTXI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:AQB, NAS:DRNA, OTCPK:PMCB, OTCPK:CWBR, OTCPK:ONCYF, OTCPK:ARTH, NAS:ARQL, NAS:KMPH, AMEX:SYN, NAS:CASI, NAS:XENE, NAS:CAPR, NAS:LPTX, NAS:AVEO, NAS:VSTM, NAS:EIGR, NAS:ALDX, OTCPK:SLNCF, NAS:SRRA, NAS:KALV » details
Traded in other countries:GTU1.Germany,
Headquarter Location:USA
GTx Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of small molecules for treatment of cancer, including treatments for breast and prostate cancer and other medical conditions.

GTx develops and markets small-molecule drugs that selectively target hormone pathways. The firm's only marketed drug, Fareston, treats metastatic breast cancer. The firm is developing Acapodene to manage the side effects of prostate cancer medications and to prevent prostate cancer in a subset of men with high-risk lesions. GTx also has a drug for cancer-related muscle loss, Ostarine, in its pipeline.

Top Ranked Articles about GTx Inc

Insider Invests in GTx Company has been gaining momentum since the start of the 4th quarter
The Pyramid Peak, a charitable organization that was founded by guru Mason Hawkins (Trades, Portfolio), purchased 7,716,049 shares of GTx Inc. (NASDAQ:GTXI) for 81 cents per share Oct. 14, according to a Form 4 filing with the Securities and Exchange Commission. Read more...

Ratios

vs
industry
vs
history
PB Ratio 3.44
GTXI's PB Ratio is ranked lower than
52% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. GTXI: 3.44 )
Ranked among companies with meaningful PB Ratio only.
GTXI' s PB Ratio Range Over the Past 10 Years
Min: 0.43  Med: 3.75 Max: 18500
Current: 3.44
0.43
18500
EV-to-EBIT -1.82
GTXI's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. GTXI: -1.82 )
Ranked among companies with meaningful EV-to-EBIT only.
GTXI' s EV-to-EBIT Range Over the Past 10 Years
Min: -18.1  Med: -3.15 Max: 12.8
Current: -1.82
-18.1
12.8
EV-to-EBITDA -1.82
GTXI's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. GTXI: -1.82 )
Ranked among companies with meaningful EV-to-EBITDA only.
GTXI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -21.6  Med: -3.2 Max: 10.4
Current: -1.82
-21.6
10.4
Current Ratio 5.27
GTXI's Current Ratio is ranked higher than
55% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. GTXI: 5.27 )
Ranked among companies with meaningful Current Ratio only.
GTXI' s Current Ratio Range Over the Past 10 Years
Min: 1.06  Med: 6.68 Max: 13.63
Current: 5.27
1.06
13.63
Quick Ratio 5.27
GTXI's Quick Ratio is ranked higher than
56% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. GTXI: 5.27 )
Ranked among companies with meaningful Quick Ratio only.
GTXI' s Quick Ratio Range Over the Past 10 Years
Min: 1.06  Med: 6.68 Max: 13.54
Current: 5.27
1.06
13.54

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -36.10
GTXI's 3-Year Average Share Buyback Ratio is ranked lower than
81% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. GTXI: -36.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GTXI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -65  Med: -19.9 Max: 0
Current: -36.1
-65
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 3.98
GTXI's Price-to-Net-Cash is ranked lower than
52% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. GTXI: 3.98 )
Ranked among companies with meaningful Price-to-Net-Cash only.
GTXI' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.97  Med: 6.02 Max: 28.4
Current: 3.98
2.97
28.4
Price-to-Net-Current-Asset-Value 3.47
GTXI's Price-to-Net-Current-Asset-Value is ranked higher than
53% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. GTXI: 3.47 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
GTXI' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.86  Med: 5.87 Max: 58.33
Current: 3.47
2.86
58.33
Price-to-Tangible-Book 3.46
GTXI's Price-to-Tangible-Book is ranked higher than
55% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. GTXI: 3.46 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
GTXI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.75  Med: 5.78 Max: 56.91
Current: 3.46
2.75
56.91
Earnings Yield (Greenblatt) % -54.95
GTXI's Earnings Yield (Greenblatt) % is ranked lower than
84% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. GTXI: -54.95 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GTXI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 7.8  Med: 169.8 Max: 3985.8
Current: -54.95
7.8
3985.8

More Statistics

EPS (TTM) $ -1.22
Beta1.76
Short Percentage of Float3.74%
52-Week Range $4.01 - 11.19
Shares Outstanding (Mil)16.04

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) -0.15
EPS without NRI ($) -0.15
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for GTXI

Headlines

Articles On GuruFocus.com
Insider Invests in GTx Oct 18 2016 
Weekly CEO Sells Highlight: GTx, Inc, VIVUS, Inc, Time Warner Inc. Jul 22 2012 
Weekly CEO Sells Highlight: GTX, Signet Group, Qlik Tech, Voxx Apr 16 2012 
GTx Inc. Reports Operating Results (10-Q) Nov 09 2010 
GTx Inc. Reports Operating Results (10-Q) Aug 09 2010 
GTx Inc. Reports Operating Results (10-Q) May 04 2010 
GTx Inc. Reports Operating Results (10-Q) Nov 09 2009 
GTx Inc. Reports Operating Results (10-Q) Aug 10 2009 
GTx Inc. Reports Operating Results (10-Q) May 11 2009 

More From Other Websites
GTx reports 4Q loss Mar 15 2017
GTx Provides Corporate Update and Reports Fourth Quarter and Year-End 2016 Financial Results Mar 15 2017
GTx, Inc. to Report Fourth Quarter and Full Year 2016 Financial Results on March 15, 2017 Mar 07 2017
Is GTx, Inc. (GTXI) A Good Stock To Buy? Dec 16 2016
GTx Reports Results from Ongoing Enobosarm Phase 2 Clinical Trial in ER+/AR+ Breast Cancer Dec 08 2016
GTx Declares 1-For-10 Reverse Stock Split (GTXI) Dec 06 2016
GTx, Inc. Announces 1-for-10 Reverse Stock Split Dec 05 2016
GTx, Inc. :GTXI-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016 Dec 01 2016
Enobosarm Meets Pre-Specified Primary Efficacy Endpoint in Ongoing Phase 2 Clinical Trial in ER+/AR+... Nov 28 2016
GTx Announces Webcast of Corporate Presentation at the 28th Annual Piper Jaffray Healthcare... Nov 23 2016
Blog Coverage GTx Inc. Enobosarm Achieves Stage 1 Milestone Nov 17 2016
GTx Achieves Second Stage 1 Milestone in Phase 2 Clinical Trial of Enobosarm in ER+/AR+ Breast... Nov 16 2016
GTx Announces Webcast of Corporate Presentation at the Stifel 2016 Healthcare Conference Nov 11 2016
GTx Provides Corporate Update and Reports Third Quarter 2016 Financial Results Nov 03 2016
Insider Invests in GTx Oct 18 2016
GTx Announces $14.0 Million Registered Direct Common Stock Offering Oct 12 2016
GTx Announces Webcast of Corporate Presentation at Baird’s 2016 Healthcare Conference Sep 02 2016
GTx Appoints Dr. Garry Neil to Board of Directors Sep 01 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)